Karyopharm Therapeutics, Inc. (KPTI)
8.86
-0.16
(-1.77%)
USD |
NASDAQ |
May 07, 16:00
8.86
0.00 (0.00%)
After-Hours: 20:00
Karyopharm Therapeutics SG&A Expense (TTM) : 105.21M for Dec. 31, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Gilead Sciences, Inc. | 8.398B |
| Catalyst Pharmaceuticals, Inc. | 171.18M |
| Alnylam Pharmaceuticals, Inc. | 1.293B |
| Oncolytics Biotech, Inc. | 10.90M |
| Agios Pharmaceuticals, Inc. | 187.06M |